Promise of faster R&D in Merck & Co's venture with Accenture

20 September 2018

A cloud-based informatics platform being launched by US pharma giant Merck & Co (NYSE: MRK) and Accenture (NYSE: CAN) has been launched with the claim that it will improve productivity, efficiency and innovation in the early stages of drug development.

The partners want to enable an ecosystem that accelerates innovation by creating open, industry-standard application programming interfaces for core research functions, allowing researchers to rapidly adopt new capabilities.

Built on Amazon Web Services, the platform is for life sciences researchers and informatics professionals, helping them to quickly aggregate, access and analyze research data from multiple applications. Data will now be accessible through a single set of interfaces, with integrated workflow, reporting and analytics capabilities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK